

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/193983 A2

(43) International Publication Date
30 September 2021 (30.09.2021)

(51) International Patent Classification:

C07K 14/605 (2006.01) *A61P 1/08* (2006.01)
A61K 38/26 (2006.01) *A61P 3/04* (2006.01)
A61P 1/04 (2006.01) *A61P 3/10* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(21) International Application Number:

PCT/JP2021/014422

(22) International Filing Date:

25 March 2021 (25.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/994,721 25 March 2020 (25.03.2020) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPAN-
NY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-
ku, Osaka-shi, Osaka 541-0045 (JP).

(72) Inventors: **HENNINOT, Antoine Charles Olivier**; c/o
Takeda California, Inc., 9625 Towne Centre Way, San
Diego, California 92121 (US). **COLE, Derek Cecil**; c/
o Takeda California, Inc., 9625 Towne Centre Way, San
Diego, California 92121 (US). **SCORAH, Nicholas**; c/
o Takeda California, Inc., 9625 Towne Centre Way, San
Diego, California 92121 (US).

(74) Agent: **UMEDA, Shinsuke** et al.; Ohno & Partners,
Marunouchi Kitaguchi Building 21F, 6-5, Marunouchi 1-
chome, Chiyoda-ku, Tokyo 1000005 (JP).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF

(57) Abstract: The present disclosure provides GIP receptor agonist peptide compounds suitable for once per week dosing (QW), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided.



WO 2021/193983 A2